186 related articles for article (PubMed ID: 30778596)
1. Assessment of the FDA Risk Evaluation and Mitigation Strategy for Transmucosal Immediate-Release Fentanyl Products.
Rollman JE; Heyward J; Olson L; Lurie P; Sharfstein J; Alexander GC
JAMA; 2019 Feb; 321(7):676-685. PubMed ID: 30778596
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the Extended-Release/Long-Acting Opioid Prescribing Risk Evaluation and Mitigation Strategy Program by the US Food and Drug Administration: A Review.
Heyward J; Olson L; Sharfstein JM; Stuart EA; Lurie P; Alexander GC
JAMA Intern Med; 2020 Feb; 180(2):301-309. PubMed ID: 31886822
[TBL] [Abstract][Full Text] [Related]
3. Association of a Risk Evaluation and Mitigation Strategy Program With Transmucosal Fentanyl Prescribing.
Fleischman W; Auth D; Shah ND; Agrawal S; Ross JS
JAMA Netw Open; 2019 Mar; 2(3):e191340. PubMed ID: 30924899
[TBL] [Abstract][Full Text] [Related]
4. Primary care physician opinion survey on FDA opioid risk evaluation and mitigation strategies.
Slevin KA; Ashburn MA
J Opioid Manag; 2011; 7(2):109-15. PubMed ID: 21561034
[TBL] [Abstract][Full Text] [Related]
5. Shared risk evaluation mitigation strategy for all immediate-release transmucosal fentanyl dosage forms.
Food And Drug Administration, Public Health Service, U.S. Department Of Health And Human Services
J Pain Palliat Care Pharmacother; 2012 Jun; 26(2):123-6. PubMed ID: 22764848
[TBL] [Abstract][Full Text] [Related]
6. The Prevalence of Off-label Prescribing of Transmucosal Immediate-Release Fentanyl in France.
Guastella V; Delorme J; Chenaf C; Authier N
J Pain Symptom Manage; 2022 Jun; 63(6):980-987. PubMed ID: 35192879
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of Risk Minimization Measures for Fentanyl Buccal Tablet (FENTORA) in Canada: A Mixed-Methods Evaluation Using Surveys, Medical Chart Records and Web Surveillance.
Kaplan S; Bergamasco A; Sergerie M; Castilloux AM; Moride Y
Drug Saf; 2020 Feb; 43(2):163-177. PubMed ID: 31691255
[TBL] [Abstract][Full Text] [Related]
8. ER/LA Opioid Analgesics REMS: Overview of Ongoing Assessments of Its Progress and Its Impact on Health Outcomes.
Cepeda MS; Coplan PM; Kopper NW; Maziere JY; Wedin GP; Wallace LE
Pain Med; 2017 Jan; 18(1):78-85. PubMed ID: 27373304
[TBL] [Abstract][Full Text] [Related]
9. SCOPE of Pain: An Evaluation of an Opioid Risk Evaluation and Mitigation Strategy Continuing Education Program.
Alford DP; Zisblatt L; Ng P; Hayes SM; Peloquin S; Hardesty I; White JL
Pain Med; 2016 Jan; 17(1):52-63. PubMed ID: 26304703
[TBL] [Abstract][Full Text] [Related]
10. Risk evaluation and mitigation strategies (REMS): educating the prescriber.
Nicholson SC; Peterson J; Yektashenas B
Drug Saf; 2012 Feb; 35(2):91-104. PubMed ID: 22171604
[TBL] [Abstract][Full Text] [Related]
11. Increase your Confidence in Opioid Prescribing: Marketing Messages in Continuing Medical Education Activities on ER/LA Opioids.
Goodwin B; Lim HD; Butler J; Paglia D; Dempsey MT; O Connor B; Fugh-Berman A
Pain Physician; 2021 Aug; 24(5):E529-E538. PubMed ID: 34323440
[TBL] [Abstract][Full Text] [Related]
12. Controlled Substance Prescribing Patterns--Prescription Behavior Surveillance System, Eight States, 2013.
Paulozzi LJ; Strickler GK; Kreiner PW; Koris CM;
MMWR Surveill Summ; 2015 Oct; 64(9):1-14. PubMed ID: 26469747
[TBL] [Abstract][Full Text] [Related]
13. A safe in-home disposal system with every opioid prescription? Food and Drug Administration is considering a potential new Risk Evaluation and Mitigation Strategy that could impact pharmacists.
Stubbings J; Crawford SY; Menighan TE
J Am Pharm Assoc (2003); 2022; 62(2):413-418. PubMed ID: 34872856
[TBL] [Abstract][Full Text] [Related]
14. ER/LA opioid REMS and accredited education: Survey results provide insight into clinical roles, educational needs, and learner preferences.
Kear C; McKeithen T; Robertson S
Subst Abus; 2017; 38(2):145-149. PubMed ID: 28418777
[TBL] [Abstract][Full Text] [Related]
15. Assessment of Potentially Inappropriate Prescribing of Opioid Analgesics Requiring Prior Opioid Tolerance.
Jeffery MM; Chaisson CE; Hane C; Rumanes L; Tucker J; Hang L; McCoy R; Chen CL; Bicket MC; Hooten WM; Larochelle M; Becker WC; Kornegay C; Racoosin JA; Sanghavi D
JAMA Netw Open; 2020 Apr; 3(4):e202875. PubMed ID: 32293684
[TBL] [Abstract][Full Text] [Related]
16. [Comparison of hospital consumption of immediate-release fentanyl: use or abuse?].
Arrieta Loitegui M; Caro Teller JM; Rosas Espinoza C; Ferrari Piquero JM
Rev Esp Salud Publica; 2020 Jul; 94():. PubMed ID: 32719309
[TBL] [Abstract][Full Text] [Related]
17. Transmucosal Immediate-Release Fentanyl for Breakthrough Cancer Pain: Opportunities and Challenges for Use in Palliative Care.
Chang A; Roeland EJ; Atayee RS; Revta C; Ma JD
J Pain Palliat Care Pharmacother; 2015 Sep; 29(3):247-60. PubMed ID: 26368648
[TBL] [Abstract][Full Text] [Related]
18. Patient and Caregiver Experiences With and Perceptions of Risk Evaluation and Mitigation Strategy Programs With Elements to Assure Safe Use.
Sarpatwari A; Brown BL; McGraw SA; Dejene SZ; Abdurrob A; Santiago Ortiz AJ; Kesselheim AS
JAMA Netw Open; 2022 Jan; 5(1):e2144386. PubMed ID: 35050352
[TBL] [Abstract][Full Text] [Related]
19. Evolution of opioid risk management and review of the classwide REMS for extended-release/long-acting opioids.
Stanos S
Phys Sportsmed; 2012 Nov; 40(4):12-20. PubMed ID: 23306411
[TBL] [Abstract][Full Text] [Related]
20. Class-wide REMS for extended-release and long-acting opioids: potential impact on pharmacies.
Matthews ML
J Am Pharm Assoc (2003); 2013; 53(1):e1-7. PubMed ID: 23636166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
